×

To enhance security, Multi-Factor Authentication (MFA) is mandatory for all HL7 users. More information

 

FHIR to CDASH (PSS in Confluence)

Basics

FHIR to CDASH (PSS in Confluence)

1636
Ballot - STU


FHIR Implementation Guide

Implementation Guide

Details

The overarching goal of this project is to improve interoperability, and facilitate the exchange of data from EHRs to clinical research submission-ready datasets. Building upon previous work on the FDA eSource grant, the PHUSE Research on FHIR projects, and the CDMH project, CDISC will collaborate with HL7, TransCelerate BioPharma and other potential partners to complete the development of a fully SME reviewed/approved FHIR-to-CDASH mappings for seven core domains (AE, CM, DM, MH, PR and VS). The mappings will be jointly balloted by CDISC and HL7 using their respective governance processes. Based on potential gaps identified through the mapping activities, CDISC standards may be enhanced/expanded. This will aid in either potentially eliminating and/or reducing such gaps that account for RWD digital sources (e.g., EHRs, ePROs, TeleHealth, etc.) and to improve interoperability.

The official authoritative FHIR-to-CDASH mappings will be published as: 1) FHIR IG and 2) CDISC Library (CDISC's MDR) as either HTML, JSON or XML media types. Both publication formats will be made freely accessible for use. Making the mappings available via the CDISC Library API permits software vendors to integrate within their systems and to use them to automate eSource and other such related activities. In addition, the mappings will include FHIR R5 draft mapping solutions and mitigation instructions to aid in future maintenance updates.

The project will collaborate with CDISC, Vulcan, PHUSE, TransCelerate BioPharma, and other potential organizations to review the mappings for consistency and quality purposes as well as to create examples to aid implementer's.


The FDA mandates that clinical trial data used to support approval of drugs and devices is submitted using CDISC standards. However, much of the research is conducted using clinical systems where data is typically exposed and shared as FHIR. Having standardized mappings for converting that clinical data for research use will save significant time on redundant data entry, independent mapping exercises and conversion issues.



Formal mappings expressed as a FHIR IG balloted as informative: January 2020 ballot cycle


https://confluence.hl7.org/pages/viewpage.action?pageId=86967359

CDISC, PHUSE, TransCelerate BioPharma, IHE?


Regulatory Agency, Standards Development Organizations (SDOs)

TBD




Yes


Yes

2025 August: TSC approved a 2 year extension for FHIR to CDISC Joint Mapping Implementation Guide v1.0.0 - STU 1 2021 November: Smita Hastak requested project to be un-archived. 2021 September: Published informative artifact. PMO archiving project.
Organization & Realm

Universal

People

Rhonda Facile, Mike Hamidi



Biomedical Research and Regulation Work Group


Status & Dates

Active

STU - Test Period/Accepting Comments

06/16/2020

09/01/2027

2027 Sept WGM/Ballot

09/01/2027

2027 Sept WGM/Ballot

2021 Jan Ballot Cycle Info: STU Ballot Results: Did not meet basic vote requirements. 14 Negatives to reconcile Document Name: HL7 FHIR Implementation Guide: FHIR to CDISC Mappings, Release 1
Approvals

08/31/2020


Not Needed


All Received




System Info